Teneligliptin (hydrobromide)

Teneligliptin (hydrobromide)

• CAS Number: 906093-29-6
• UNSPSC Description: Teneligliptin (MP-513) hydrobromide is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus[1][2][3][4][5][6][7][8].
• Target Antigen: AMPK; Apoptosis; Dipeptidyl Peptidase; Interleukin Related; JNK; NF-κB; NOD-like Receptor (NLR); p38 MAPK; Reactive Oxygen Species
• Type: Reference compound
• Related Pathways: Apoptosis;Epigenetics;Immunology/Inflammation;MAPK/ERK Pathway;Metabolic Enzyme/Protease;NF-κB;PI3K/Akt/mTOR
• Applications: Metabolism-sugar/lipid metabolism
• Field of Research: Metabolic Disease; Neurological Disease; Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/Teneligliptin-hydrobromide.html
• Solubility: DMSO : ≥ 100 mg/mL|H2O : ≥ 200 mg/mL
• Smiles: O=C(N1CSCC1)[C@H]2NC[C@@H](N3CCN(C4=CC(C)=NN4C5=CC=CC=C5)CC3)C2.[2.5 HBr]
• Molecular Weight: 628.86
• References & Citations: [1]Yoshida T, et al. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem. 2012 Oct 1;20(19):5705-19.|[2]Guo D, et al. Beneficial effects of combination therapy of canagliflozin and teneligliptin on diabetic polyneuropathy and β-cell volume density in spontaneously type 2 diabetic Goto-Kakizaki rats. Metabolism. 2020 Jun;107:154232.|[3]Zhang GL, et al. Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. World J Diabetes. 2024 Apr 15;15(4):724-734.|[4]Fukuda-Tsuru S, et al. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Eur J Pharmacol. 2014 Jan 15;723:207-15.|[5]Zhang Z, et al. Teneligliptin protects against hypoxia/reoxygenation-induced endothelial cell injury. Biomed Pharmacother. 2019 Jan;109:468-474.|[6]Peng W, et al. Teneligliptin prevents doxorubicin-induced inflammation and apoptosis in H9c2 cells. Arch Biochem Biophys. 2020 Apr 15;683:108238.|[7]Liu X, et al. Teneligliptin inhibits lipopolysaccharide-induced cytotoxicity and inflammation in dental pulp cells. Int Immunopharmacol. 2019 Aug;73:57-63.|[8]Elumalai S, et al. High glucose-induced PRDX3 acetylation contributes to glucotoxicity in pancreatic β-cells: Prevention by Teneligliptin. Free Radic Biol Med. 2020 Nov 20;160:618-629. Cosmetics. 2024 Mar 1, 11(2), 35.|Antioxidants (Basel). 2021 Sep 9;10(9):1438.|Antioxidants (Basel). 2023 Jul 24;12(7):1478.|Chem Res Toxicol. 2020 Aug 17;33(8):2164-2171.|Eur J Med Chem. 2021 Feb 15;212:113030.|Nephrol Dial Transplant. 2019 Oct 1;34(10):1669-1680.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched